Skip to content

Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research

Why single-cell technologies are vital for Endometriosis research


Learn why single-cell technologies are vital for Endometriosis research

Endometriosis is a debilitating disease that affects 10% of women and girls of reproductive age. There is no cure, no certain cause and no non-invasive method of diagnosing the disease, leading to a reduced quality of life for the patients and a significant socio-economic burden.

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of this disease requires a novel research approach by single-cell analysis. Therefore, Prof. Dr. med. Müller started collaborating with Scailyte AG, the specialist in single-cell analysis. In a joint project, they strive to develop a non-invasive diagnosis method, and potentially a prognostic method to reduce the suffering of endometriosis patients. Prof. Mueller is a renowned gynaecologist and gynaecological oncologist, and managing director of the Women’s Health Clinic at the University Hospital of Bern (Inselspital). He is the founding member and current president of the working group for Endoscopic Gynecology.

Join this webinar with Prof. Mueller, in cooperation with Scailyte, to learn more about “Why single-cell technologies are vital for Endometriosis research.”

Watch the webinar here: https://youtu.be/XPmhGRy-1AY

 

 

About Scailyte

Scailyte AG is a data-driven biomarker discovery company, founded in Luzern, Switzerland in 2017. The ETH Spin-off is using cutting edge technologies within the single-cell space and a proprietary biomarker discovery platform to develop clinical diagnostic applications in oncology and women’s health. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018. www.scailyte.com
ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Recent News

Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Recent News

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Recent News

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News

Scailyte Quarterly Update, April 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

01 /04

VACANCY: Regulatory Affairs / Quality Management Specialist

We are currently developing a first-in-class in vitro diagnostic tool for Endometriosis aiming at cu

Read more

Scailyte Webinar - Why single-cell technologies are vital for Endometriosis research

Prof. Dr Michael D. Mueller is an expert in endometriosis and women’s health. The complexity of th

Read more

Recent News

02 /04

Single-Cell Discovery Grant in Oncology and Immunology

Open grant call of up to 100K Euro aimed at addressing unmet clinical needs in Oncology and Immunolo

Read more

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

03 /04

Scailyte Quarterly Update, June 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Scailyte announces Michael Brenner, of Harvard Medical School, as an advisor to its Board of Directors

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News